Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic therapy

D Collen1

  • 1Center for Molecular and Vascular Biology, University of Leuven, Belgium. desire.collen@med.kuleuven.ac.be

Thrombosis and Haemostasis
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

New thrombolytic agents are being developed to overcome limitations of current treatments for acute myocardial infarction. Research focuses on improved potency, specificity, and fibrin-selectivity for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired fibrinolysis and the risk for coronary heart disease.

Circulation·1996
Same author

Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

European journal of biochemistry·1996
Same author

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Circulation·1996
Same author

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Thrombosis and haemostasis·1996
Same author

Role of tissue factor in embryonic blood vessel development.

Nature·1996
Same author

Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.

The Journal of biological chemistry·1996
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biotechnology

Background:

  • Current thrombolytic agents for acute myocardial infarction have limitations.
  • These include resistance to reperfusion, reocclusion, and bleeding complications.

Purpose of the Study:

  • To explore novel thrombolytic agents with enhanced efficacy and safety.
  • To address the limitations of existing reperfusion therapies.

Main Methods:

  • Developing mutants and variants of plasminogen activators.
  • Creating chimeric plasminogen activators.
  • Investigating plasminogen activators from animal or bacterial sources.

Main Results:

  • New agents evaluated in animal models of thrombosis.

Related Experiment Videos

  • Some agents progressed to pilot studies in acute myocardial infarction patients.
  • A few advanced to large clinical trials with mortality endpoints.

    • Conclusions:

    • Further dose-finding studies and randomized clinical trials are needed.
    • The relative therapeutic benefit of new agents must be defined against classical thrombolytics.